Voyager Therapeutics (NASDAQ:VYGR) is set to issue its quarterly earnings data after the market closes on Wednesday, November 7th. Analysts expect the company to announce earnings of ($0.78) per share for the quarter.
Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, August 7th. The company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.13). Voyager Therapeutics had a negative net margin of 731.88% and a negative return on equity of 80.68%. The company had revenue of $2.58 million during the quarter, compared to the consensus estimate of $3.00 million. On average, analysts expect Voyager Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
VYGR stock traded up $0.22 during trading on Thursday, hitting $13.79. The company had a trading volume of 7,524 shares, compared to its average volume of 299,279. Voyager Therapeutics has a one year low of $11.54 and a one year high of $31.91. The stock has a market capitalization of $443.08 million, a PE ratio of -5.26 and a beta of 2.94.
A number of equities analysts have issued reports on VYGR shares. Morgan Stanley cut Voyager Therapeutics from an “overweight” rating to an “equal” rating in a report on Monday, September 10th. BidaskClub cut Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, September 8th. Zacks Investment Research upgraded Voyager Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 11th. BTIG Research restated a “buy” rating and set a $32.00 price target on shares of Voyager Therapeutics in a report on Monday, September 10th. Finally, ValuEngine cut Voyager Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, September 17th. Four equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $30.63.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Further Reading: Understanding Stock Ratings
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.